By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: A Von Eschenbach Sighting
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > A Von Eschenbach Sighting
BusinessPolicy & Law

A Von Eschenbach Sighting

gooznews
gooznews
Share
3 Min Read
SHARE

Former Food and Drug Administration commissioner Andrew Von Eschenbach, who ran the agency from 2005 to 2009 and has now decamped to the conservative Manhattan Institute, had this advice for reforming the agency in this morning’s Wall Street Journal:

(Reform) means creating FDA pilot programs to bring promising therapies to patients more quickly by allowing them to be approved based on safety, with efficacy to be proven in later trials.

Former Food and Drug Administration commissioner Andrew Von Eschenbach, who ran the agency from 2005 to 2009 and has now decamped to the conservative Manhattan Institute, had this advice for reforming the agency in this morning’s Wall Street Journal:

(Reform) means creating FDA pilot programs to bring promising therapies to patients more quickly by allowing them to be approved based on safety, with efficacy to be proven in later trials.

Right. Give a drug industry that already fails to complete two-thirds of its mandated post-marketing trials a blank check to dump hundreds of unproven molecules on the market so that insurers, including Medicare, will have to pay for them. I’m surprised he didn’t also call for balancing the budget.

Now, to be fair, he also said that “the product could be approved for marketing with every eligible patient entered in a registry so the company and the FDA can establish efficacy through post-market studies.” In essence, he’s saying let’s abandon the gold-standard of double-blind, placebo-controlled clinical trials for determining efficacy, and substitute post-hoc epidemiological studies based on registry data.

I’m a big fan of registries. I believe their data can be used to determine efficacy. I look forward to the day when there are registries up and running for all the borderline drugs and devices that are already on the market; registries with the scope and controls that independent scientists agree are adequate for reaching conclusions about efficacy in a post-marketing setting. On that day, we can talk about extending such registries on a pilot basis to some experimental medicines that have passed their Phase I safety trials.

TAGGED:FDAhealth reform
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

uv protection in winter
Winter Sun Safety: Why UV Protection Matters Year-Round
Health
October 29, 2025
Nurse Scheduling Software
Evaluating 7 Best Nurse Scheduling Software
Nursing Technology
October 28, 2025
contamination
Batch Failures And The Hidden Costs Of Contamination
Health Infographics
October 21, 2025
Medication Management For Seniors
Simplifying Medication Management For Seniors
Infographics Senior Care
October 21, 2025

You Might also Like

family-owned healthcare business
Global HealthcareHealth carePolicy & Law

Shareholders’ Agreement Benefits for Family-Owned Healthcare Firms

May 27, 2021

FDA Approves Diabetes Pill

May 2, 2011
The Outcomes That Matter To Patients
Hospital AdministrationPublic Health

The Outcomes That Matter to Patients

September 15, 2013
eHealthHealth careHospital AdministrationMarketing

What To Know About The Importance Of Healthcare Marketing

November 23, 2019
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?